Physician profile
Amit Saxena
NPI 1851507362
$16,252.48
in general payments reported to CMS, 2019-2025
12 companies · $3,741 in 2025
The $3,741 reported for 2025 was more than what 97% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2021: $1,500 · 2022: $4,553 · 2023: $4,331 · 2024: $2,013 · 2025: $3,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,398 · Food and Beverage: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,397.50 |
| Food and Beverage | $686.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $9,673.50 | 2021-2025 | Saphnelo |
| Astrazeneca Uk Limited | $5,370.00 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $284.14 | 2024-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $257.24 | 2022-2024 | Uzedy |
| Novo Nordisk INC | $250.00 | 2021-2022 | |
| Viatris Specialty LLC | $125.00 | 2025 | Yupelri |
| Ferring Pharmaceuticals INC. | $118.08 | 2024 | Rebyota |
| Avanir Pharmaceuticals, INC. | $115.00 | 2019 | |
| Acadia Pharmaceuticals INC | $34.52 | 2023 | Nuplazid |
| Alkermes, INC. | $25.00 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Saxena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.